367 related articles for article (PubMed ID: 29776658)
21. A 26-week feasibility study comparing the efficacy and safety of modified-release prednisone with immediate-release prednisolone in newly diagnosed cases of giant cell arteritis.
Raine C; Stapleton PP; Merinopoulos D; Maw WW; Achilleos K; Gayford D; Mapplebeck S; Mackerness C; Schofield P; Dasgupta B
Int J Rheum Dis; 2018 Jan; 21(1):285-291. PubMed ID: 28791802
[TBL] [Abstract][Full Text] [Related]
22. Do Early Diagnosis and Glucocorticoid Treatment Decrease the Risk of Permanent Visual Loss and Early Relapses in Giant Cell Arteritis: A Prospective Longitudinal Study.
Hocevar A; Rotar Z; Jese R; Semrl SS; Pizem J; Hawlina M; Tomsic M
Medicine (Baltimore); 2016 Apr; 95(14):e3210. PubMed ID: 27057850
[TBL] [Abstract][Full Text] [Related]
23. Ustekinumab for the treatment of refractory giant cell arteritis.
Conway R; O'Neill L; O'Flynn E; Gallagher P; McCarthy GM; Murphy CC; Veale DJ; Fearon U; Molloy ES
Ann Rheum Dis; 2016 Aug; 75(8):1578-9. PubMed ID: 27143653
[No Abstract] [Full Text] [Related]
24. Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial.
Venhoff N; Schmidt WA; Lamprecht P; Tony HP; App C; Sieder C; Legeler C; Jentzsch C; Thiel J
Trials; 2021 Aug; 22(1):543. PubMed ID: 34404463
[TBL] [Abstract][Full Text] [Related]
25. Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis.
Monti S; Águeda AF; Luqmani RA; Buttgereit F; Cid M; Dejaco C; Mahr A; Ponte C; Salvarani C; Schmidt W; Hellmich B
RMD Open; 2019; 5(2):e001003. PubMed ID: 31673411
[TBL] [Abstract][Full Text] [Related]
26. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.
Unizony S; Arias-Urdaneta L; Miloslavsky E; Arvikar S; Khosroshahi A; Keroack B; Stone JR; Stone JH
Arthritis Care Res (Hoboken); 2012 Nov; 64(11):1720-9. PubMed ID: 22674883
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of Methotrexate in Real-world Management of Giant Cell Arteritis: A Case-control Study.
Koster MJ; Yeruva K; Crowson CS; Muratore F; Labarca C; Warrington KJ
J Rheumatol; 2019 May; 46(5):501-508. PubMed ID: 30647171
[TBL] [Abstract][Full Text] [Related]
28. Comparing treatment options for large vessel vasculitis.
Macaluso F; Marvisi C; Castrignanò P; Pipitone N; Salvarani C
Expert Rev Clin Immunol; 2022 Aug; 18(8):793-805. PubMed ID: 35714219
[TBL] [Abstract][Full Text] [Related]
29. Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study.
Samson M; Devilliers H; Ly KH; Maurier F; Bienvenu B; Terrier B; Charles P; Guillevin L; Besancenot JF; Liozon E; Fauchais AL; Loffroy R; Binquet C; Audia S; Seror R; Mariette X; Bonnotte B
Eur J Intern Med; 2018 Nov; 57():96-104. PubMed ID: 30054122
[TBL] [Abstract][Full Text] [Related]
30. Risk of Diabetes Mellitus among Patients Diagnosed with Giant Cell Arteritis or Granulomatosis with Polyangiitis: Comparison with the General Population.
Faurschou M; Ahlström MG; Lindhardsen J; Obel N; Baslund B
J Rheumatol; 2017 Jan; 44(1):78-83. PubMed ID: 27744394
[TBL] [Abstract][Full Text] [Related]
31. Giant cell arteritis: what is new in the preclinical and early clinical development pipeline?
Harkins P; Conway R
Expert Opin Investig Drugs; 2022 Sep; 31(9):921-932. PubMed ID: 34106030
[TBL] [Abstract][Full Text] [Related]
32. Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions.
Sugihara T; Hasegawa H; Uchida HA; Yoshifuji H; Watanabe Y; Amiya E; Maejima Y; Konishi M; Murakawa Y; Ogawa N; Furuta S; Katsumata Y; Komagata Y; Naniwa T; Okazaki T; Tanaka Y; Takeuchi T; Nakaoka Y; Arimura Y; Harigai M; Isobe M;
Arthritis Res Ther; 2020 Apr; 22(1):72. PubMed ID: 32264967
[TBL] [Abstract][Full Text] [Related]
33. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA).
Spiera RF; Mitnick HJ; Kupersmith M; Richmond M; Spiera H; Peterson MG; Paget SA
Clin Exp Rheumatol; 2001; 19(5):495-501. PubMed ID: 11579707
[TBL] [Abstract][Full Text] [Related]
34. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.
Maz M; Chung SA; Abril A; Langford CA; Gorelik M; Guyatt G; Archer AM; Conn DL; Full KA; Grayson PC; Ibarra MF; Imundo LF; Kim S; Merkel PA; Rhee RL; Seo P; Stone JH; Sule S; Sundel RP; Vitobaldi OI; Warner A; Byram K; Dua AB; Husainat N; James KE; Kalot MA; Lin YC; Springer JM; Turgunbaev M; Villa-Forte A; Turner AS; Mustafa RA
Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1071-1087. PubMed ID: 34235871
[TBL] [Abstract][Full Text] [Related]
35. Circulating interleukin-6 as a biomarker in a randomized controlled trial of modified-release prednisone vs immediate-release prednisolone, in newly diagnosed patients with giant cell arteritis.
Miler E; Stapleton PP; Mapplebeck S; Mackerness C; Gayford D; Aung T; Wilson L; Schofield P; Dasgupta B
Int J Rheum Dis; 2019 Oct; 22(10):1900-1904. PubMed ID: 31531960
[TBL] [Abstract][Full Text] [Related]
36. Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study.
Schönau V; Roth J; Tascilar K; Corte G; Manger B; Rech J; Schmidt D; Cavallaro A; Uder M; Crescentini F; Boiardi L; Casali M; Spaggiari L; Galli E; Kuwert T; Versari A; Salvarani C; Schett G; Muratore F
Rheumatology (Oxford); 2021 Aug; 60(8):3851-3861. PubMed ID: 33831144
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis.
Hachulla E; Boivin V; Pasturel-Michon U; Fauchais AL; Bouroz-Joly J; Perez-Cousin M; Hatron PY; Devulder B
Clin Exp Rheumatol; 2001; 19(2):171-6. PubMed ID: 11326479
[TBL] [Abstract][Full Text] [Related]
38. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis.
Mahr AD; Jover JA; Spiera RF; Hernández-García C; Fernández-Gutiérrez B; Lavalley MP; Merkel PA
Arthritis Rheum; 2007 Aug; 56(8):2789-97. PubMed ID: 17665429
[TBL] [Abstract][Full Text] [Related]
39. [Treatment of giant cell arteritis].
Samson M; Greigert H; Ghesquière T; Bonnotte B
Presse Med; 2019 Sep; 48(9):968-979. PubMed ID: 31324351
[TBL] [Abstract][Full Text] [Related]
40. Positron Emission Tomography/Computerized Tomography in Newly Diagnosed Patients with Giant Cell Arteritis Who Are Taking Glucocorticoids.
Clifford AH; Murphy EM; Burrell SC; Bligh MP; MacDougall RF; Heathcote JG; Castonguay MC; Lee MS; Matheson K; Hanly JG
J Rheumatol; 2017 Dec; 44(12):1859-1866. PubMed ID: 28916549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
